Intensivmedizinische Komplikationen autoimmuner Enzephalitiden

Autoimmune Enzephalitiden weisen häufig einen schweren Verlauf mit gravierenden Komplikationen auf, sind aber diagnostisch oft nicht leicht zu fassen. Dieser Artikel stellt die pathophysiologischen Grundlagen dar, erläutert das klinische Erscheinungsbild und diskutiert die therapeutischen Möglichkeiten anhand der vorhandenen Datenlage und der Erfahrungen aus verschiedenen neurologisch-intensivmedizinischen Netzwerken.

• Literatur

• 1 Granerod J, Ambrose HE, Davies NW. et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10: 835-844
• 2 Sonneville R, Gault N, de Montmollin E. et al. Clinical spectrum and outcomes of patients with encephalitis requiring intensive care. Eur J Neurol 2015; 22: 6-16
• 3 Titulaer MJ, McCracken L, Gabilondo I. et al. Late-onset anti-NMDA receptor encephalitis. Neurology 2013; (17) 81: 1058-1063
• 4 Leypoldt F. Autoimmune Enzephalitiden. Fortschr Neurol Psychiatr 2013; 81: 523-538
• 5 Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; (12) 77: 179-189
• 6 Graus F, Titulaer MJ, Balu R. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404
• 7 Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res 2016; 176: 36-40
• 8 Günther A. Autoantikörper-assoziierte Enzephalitiden. In: Berrouschot J, Köhler W, Sakowitz O. Hrsg. Neurointensivmedizin kompakt 2015. Stuttgart: Thieme; 2015: 274-280
• 9 Wandinger K, Dalmau J, Borowski K. et al. Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalitis. In: Conrad K, Chan EKL, Fritzler MJ. et al., eds. From pathogenesis to therapy of autoimmune diseases – Report on the 9th Dresden Symposium on Antibodies. Lengerich: Pabst Science Publishers; 2009: 434-435
• 10 Prüss H, Dalmau J, Arolt V. et al. Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture. Nervenarzt 2010; 81: 396-408
• 11 Schmitt SE, Pargeon K, Frechette ES. et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79: 1094-1100
• 12 Titulaer MJ, McCracken L, Gabilondo I. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165
• 13 Liba Z, Sebronova V, Komarek V. et al. Prevalence and treatment of anti-NMDA receptor encephalitis. Lancet Neurol 2013; 12: 424-425
• 14 Dalmau J, Lancaster E, Martinez-Hernandez E. et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74
• 15 Dalmau J, Gleichman AJ, Hughes EG. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098
• 16 Rajagopal S. Catatonia. Adv Psychiatr Treat 2006; 13: 51-59
• 17 Kiani R, Lawden M, Eames P. et al. Anti-NMDA-receptor encephalitis presenting with catatonia and neuroleptic malignant syndrome in patients with intellectual disability and autism. BJPsych Bull 2015; 39: 32-35
• 18 Pillai SC, Mohammad SS, Hacohen Y. et al. Postencephalitic epilepsy and drug-resistant epilepsy after infectious and antibody-associated encephalitis in childhood: Clinical and etiologic risk factors. Epilepsia 2016; 57: e7-11
• 19 Reinhart K, Brunkhorst FM, Bone HG. et al. Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI). Anaesthesist 2010; 59: 347-370
• 20 Günther A, Brodoehl S, Witte OW. et al. Atypical posthypoxic MRI changes in hypermetabolic regions in anti-NMDA-receptor encephalitis. Neurology 2012; (14) 79: 720-721
• 21 Bien C. Hrsg. Immunvermittelte Erkrankungen der grauen ZNS-Substanz sowie Neurosarkoidose. Leitlinien für Diagnostik und Therapie in der Neurologie. Berlin: Deutsche Gesellschaft für Neurologie e.V. 2012. Im Internet: http://www.dgn.org/leitlinien/2396-ll-32-2012-immunvermittelte-erkrankungen-der-grauen-zns-substanz-sowie-neurosarkoidose
• 22 Ehrlich S, Fassbender CM, Blaes C. et al. Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection. Nervenarzt 2013; 84: 498-507
• 23 Melzer N, Meuth SG, Wiendl H. Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol 2013; 260: 1215-1233
• 24 Thakur KT, Motta M, Asemota AO. et al. Predictors of outcome in acute encephalitis. Neurology 2013; 27: 793-800
• 25 Sili U, Kaya A, Mert A. HSV Encephalitis Study Group. Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients. J Clin Virol 2014; 60: 112-118